BioWire Weekly - 009

Biotech News

Happy Wednesday Morning, Readers.

This week’s edition of BioWire will cover several interesting topics at the interface of biomedicine, biotechnology, and computational sciences:

• Non-hormonal male birth control, YCT-529, blocks sperm production by inhibiting retinoic acid receptor-alpha, showing early safety and effectiveness in Phase I trials.

• Charles River and Sanofi are developing AI-driven virtual control groups to reduce animal use in preclinical research, enhancing efficiency and ethical standards as part of a $300 million initiative.

• Landmark 2006 Alzheimer's paper is being retracted due to doctored images, challenging the amyloid hypothesis that plaques are the root cause of the disease and reigniting debate over its validity.

• A phase II clinical trial found no overall improvement in progressive multiple sclerosis patients treated with stem cell therapy compared to placebo, but noted improvements in walking and bladder function in a subgroup with higher disability scores.

How will these breakthroughs shape the future of medicine and technology?

Non-Hormonal Male Birth Control Shows Promising Safety and Efficacy in Early Trials

YourChoice Therapeutics claimed to have developed the first-of-its-kind non-hormonal male birth control method. Unlike traditional hormone-based options, the product named YCT-529 works by inhibiting the retinoic acid receptor-alpha (RAR-alpha), blocking sperm production by restricting vitamin A in the testes. This effectively prevents conception without hormonal side effects. Press releases claim that Preclinical studies showed 99% effectiveness and complete reversibility (Link). Typically, I confirm these findings and cite the published source material. However, I was unable to find the article and independently validate this. In other news, early Phase I testing thus far indicates that this method is safe and effective, with no significant adverse effects observed. The data has not yet been publicly shared. If true, this innovative contraceptive could offer a great alternative to traditional birth control and empower men with a reliable option.

Contract Research Organizations Begin Developing Virtual Animal Models

Charles River Laboratories and Sanofi are working together to develop virtual control groups (VCGs) in preclinical research, replacing some live animals with AI data-driven models (link). This initiative aims to reduce the number of animals used in studies while providing reliable results with historical data. The partnership is part of Charles River’s Alternative Methods Advancement Project, a $300 million, five-year program focused on researching alternatives to animal testing. While the majority of studies will continue to rely on live animal models, the project aims to enhance the efficiency and ethical standards of preclinical research.

Landmark Alzheimer’s Study Retraction

We have discussed Alzheimer’s and new emerging antibody-based therapies in a prior article (link). One highlight from this drug is that it removes plaque buildup from the brain, which relies on the theory that these plaques are the root cause of Alzheimer’s disease. Notably, the treatment shows very minor efficacy, only slightly slowing the progression of the disease. Now, there is a significant development regarding the original research that generated the plaque theory of Alzheimer's: Researchers are planning to retract the landmark 2006 Alzheimer's paper due to evidence of doctored images (link). The study, originally published in Nature, suggested that an amyloid beta protein called Aβ*56 could cause Alzheimer's disease (Lesné et al, 2006). This finding was pivotal in the amyloid hypothesis of Alzheimer's and heavily influenced subsequent research and funding. Investigations revealed manipulated data in this and other papers by co-author Sylvain Lesné. This retraction has rightfully renewed the debate about the validity of the amyloid hypothesis

Stem Cell Therapy Improves MS Symptoms

A recent phase II clinical trial investigated the efficacy of intrathecal mesenchymal stem cell-neural progenitor (MSC-NP) therapy in patients with progressive multiple sclerosis (MS) (Harris et al, 2024). The study found no significant difference in overall improvement between the MSC-NP and placebo groups. However, exploratory analysis showed notable improvements in walking and bladder function among a subgroup with higher disability scores (EDSS 6.0-6.5) treated with MSC-NPs. These findings suggest potential benefits of MSC-NP therapy for certain MS patients, although broader efficacy remains unproven.

Support:

These newsletters take a significant amount of effort to put together and are totally for the benefit of the reader. If you find these explorations valuable, there are multiple ways to show your support:

• Engage: Like or comment on posts to join the conversation.

• Subscribe: Never miss an update by subscribing to the Substack.

• Share: Help spread the word by sharing posts with friends directly or on social media.

Sources:

https://www.yourchoicetx.com/

https://www.fiercebiotech.com/research/no-hormones-no-problem-yourchoices-first-its-kind-male-birth-control-safe-men-so-far

https://www.science.org/content/article/researchers-plan-retract-landmark-alzheimers-paper-containing-doctored-images

https://www.fiercebiotech.com/cro/charles-river-and-sanofi-collab-replace-animals-virtual-controls-preclinical-research

Lesné, S., Koh, M.T., Kotilinek, L., Kayed, R., Glabe, C.G., Yang, A., Gallagher, M. and Ashe, K.H., 2006. A specific amyloid-β protein assembly in the brain impairs memory. Nature, 440(7082), pp.352-357.

Harris, V.K., Stark, J., Williams, A., Roche, M., Malin, M., Kumar, A., Carlson, A.L., Kizilbash, C., Wollowitz, J., Andy, C. and Gerber, L.M., 2024. Efficacy of intrathecal mesenchymal stem cell-neural progenitor therapy in progressive MS: results from a phase II, randomized, placebo-controlled clinical trial. Stem Cell Research & Therapy, 15(1), p.151.